CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 23 enrolled
Drug / intervention
tsDCS Dosage (A) +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03667573
NCT03667573Phase 1Completed

Spinal Excitation to Enhance Mobility in Elderly Adults

VA Office of Research and Development·interventional·Posted Sep 12, 2018·Updated Sep 13, 2023

In Brief

A Phase 1 clinical trial evaluating tsDCS Dosage (A), tsDCS Dosage (B), and 1 other intervention for Aging. Completed, enrolled 23 participants across 1 site.

Detailed Summary

Older adults with compromised walking ability have higher rates of morbidity and mortality, more hospitalizations, poorer quality of life, and are less likely to remain independent in the community. It is known that age-related changes in brain and peripheral nerves contribute to loss of walking ability. However, there is a lack of research into how the aging spinal cord affects walking. In older adults, the spinal cord is less excitable, conducts signals more slowly, and is subject to neural noise. Intervening on age-related impairment of the spinal cord to improve walking ability is a very promising but untapped area of research.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAging
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedSep 12, 2018
Enrollment StartDec 17, 2018
Primary CompletionAug 18, 2021
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.8 years ago

Interventions

tsDCS Dosage (A)device

mild electrical stimulation delivered to lumbosacral spinal cord

tsDCS Dosage (B)device

mild electrical stimulation delivered to lumbosacral spinal cord

textured shoe insolesother

textured shoe insoles